Clinical trial
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast…
NCT00083993 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00083993 |
|---|---|
| Title | Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer |
| Official title | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months |
| Enrollment | 1,236 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jun 8, 2004 |
| Last update posted | Nov 8, 2011 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: